Physician
Proano, Lawrence
Proano, Lawrence was paid $2.26M by Medicaid between Mar 2020 and Dec 2024, across 20 billing codes. Its largest line is 99283, emergency room visit (moderate) — 33% of everything it billed.
33Billing provider infoPROANO, LAWRENCE
PROVIDENCE, RI 02903
PROVIDENCE, RI 02903
33aNPI1265446538assigned 07/29/2006
33bProvider typeEmergency Medicine Physician
28Total paid$2.26M
24GClaims10,914
24DCodes billed20
24AFirst – last monthMar 2020 – Dec 2024
Compared with peers
Next to other Emergency Medicine Physician providers in Rhode Island
Rank by total paid#1 of 188
Median peer was paid$94K
This provider vs. median24×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2020 | 282 | $84K | |
| 2021 | 2,626 | $561K | |
| 2022 | 2,699 | $581K | |
| 2023 | 3,382 | $633K | |
| 2024incomplete | 1,925 | $404K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 33% | 3,002 | 2,820 | $750K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 25% | 2,348 | 2,217 | $568K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 22% | 2,539 | 2,454 | $497K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 4.7% | 784 | 688 | $106K |
| 36415 | Collection of venous blood by venipuncture | 4.6% | 730 | 625 | $103K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.3% | 214 | 205 | $51K |
| 81001 | 1.8% | 299 | 266 | $40K | |
| 80053 | Comprehensive metabolic panel | 1.5% | 256 | 227 | $33K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 1.3% | 219 | 186 | $29K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.0% | 147 | 76 | $23K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 81 | 72 | $15K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 77 | 67 | $10K |
8 more codes
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 33 | $8K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 33 | $8K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 32 | $6K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 32 | $6K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 37 | $5K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 19 | $3K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 18 | $3K |
| J3490 | Unclassified drugs | <1% | 14 | $233.91 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.